Investment Analysts’ Recent Ratings Updates for Establishment Labs (ESTA)

A number of research firms have changed their ratings and price targets for Establishment Labs (NASDAQ: ESTA):

• 10/29/2026 – Establishment Labs had its price target lowered by BTIG Research from $103.00 to $93.00. They now have a “buy” rating on the stock.
• 10/26/2026 – Establishment Labs had its price target lowered by TD Cowen from $117.00 to $95.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Establishment Labs had its “buy” rating reaffirmed by TD Cowen. They now have a $117.00 price target on the stock.
• 10/14/2026 – Establishment Labs is now covered by Stifel Nicolaus. They set a “buy” rating and a $85.00 price target on the stock.
• 9/21/2026 – Establishment Labs had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Establishment Labs Stock Performance

ESTA stock traded up $0.33 during mid-day trading on Tuesday, reaching $61.40. 463,467 shares of the stock traded hands, compared to its average volume of 519,794. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. Establishment Labs Holdings Inc. has a 52 week low of $47.22 and a 52 week high of $97.59. The business has a 50-day moving average of $66.83 and a two-hundred day moving average of $72.32. The firm has a market capitalization of $1.83 billion, a PE ratio of -47.97 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.09). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%. The business had revenue of $71.99 million during the quarter, compared to the consensus estimate of $66.81 million. During the same quarter in the previous year, the firm posted ($0.38) earnings per share. The company’s revenue for the quarter was up 33.8% on a year-over-year basis. As a group, equities analysts predict that Establishment Labs Holdings Inc. will post -1.08 EPS for the current fiscal year.

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.